keyword
MENU ▼
Read by QxMD icon Read
search

Post second line chemotherapy treatment prostate cancer

keyword
https://www.readbyqxmd.com/read/27890446/efficacy-of-therapies-after-galeterone-in-patients-with-castration-resistant-prostate-cancer
#1
Rana R McKay, Lillian Werner, Matthew Fiorillo, Jennifer Roberts, Elisabeth I Heath, Glenn J Bubley, Robert Bruce Montgomery, Mary-Ellen Taplin
BACKGROUND: Galeterone is a multi-targeted agent with activity as a CYP17 inhibitor, androgen receptor antagonist, and also causes androgen receptor degradation. It has shown meaningful anti-tumor activity with a well-tolerated safety profile in patients with castration-resistant prostate cancer (CRPC) in phase I and II studies; however, the efficacy of currently approved CRPC therapies after treatment with galeterone is unknown. In this study, we evaluate prostate specific antigen (PSA) response of non-protocol therapies following galeterone in a subset of patients treated on the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 study...
October 27, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27754846/advances-in-the-management-of-castration-resistant-prostate-cancer
#2
Chad R Ritch, Michael S Cookson
Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab)...
October 17, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27506431/-177-lu-dkfz-psma-617-therapy-in-metastatic-castration-resistant-prostate-cancer-safety-efficacy-and-quality-of-life-assessment
#3
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
August 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/26853769/a-prospective-study-examining-elder-relevant-outcomes-in-older-adults-with-prostate-cancer-undergoing-treatment-with-chemotherapy-or-abiraterone
#4
Tharsika Manokumar, Salman Aziz, Henriette Breunis, S Faraz Rizvi, Anthony M Joshua, Ian F Tannock, Shabbir M H Alibhai
BACKGROUND: Treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in fit older men (age 65+) but its impact on function is not clear. We hypothesized that chemotherapy would impair daily function in older men with mCRPC. METHODS: Men aged 65+ with mCRPC starting chemotherapy or abiraterone were enrolled in this prospective observational pilot study. Daily function was evaluated with the OARS Instrumental Activities of Daily Living (IADL) scale...
March 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/24255983/enzalutamide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-progressing-after-chemotherapy-and-abiraterone-acetate
#5
Frederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen
OBJECTIVE: The aim of this study was to record prostate-specific antigen (PSA) response and overall survival (OS) for a group of metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide following progression after abiraterone treatment in the post-chemotherapy setting. MATERIAL AND METHODS: Twenty-four mCRPC patients with progression after abiraterone treatment following primary docetaxel therapy received enzalutamide 160 mg/day...
June 2014: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/24101043/prostate-specific-antigen-changes-as-surrogate-for-overall-survival-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-second-line-chemotherapy
#6
RANDOMIZED CONTROLLED TRIAL
Susan Halabi, Andrew J Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C Solomon, Eric J Small
PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy. PATIENTS AND METHODS: Data from a phase III trial of patients with mCRPC randomly assigned to cabazitaxel plus prednisone (C + P) or mitoxantrone plus prednisone were used...
November 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/23896627/are-post-docetaxel-treatments-effective-in-patients-with-castration-resistant-prostate-cancer-and-performance-of-2-a-meta-analysis-of-published-trials
#7
R Iacovelli, A Altavilla, G Procopio, S Bracarda, M Santoni, S Cascinu, E Cortesi
BACKGROUND: About 20% of patients with prostate cancer have an ECOG performance status (PS) 2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2. METHODS: PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected...
December 2013: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/23107383/progress-in-emerging-therapies-for-advanced-prostate-cancer
#8
REVIEW
Stéphane Oudard
The landscape of prostate cancer treatment is rapidly changing as extensive research into potential therapies yields new options. In this article, the literature is reviewed to identify emerging therapies for advanced prostate cancer. Emphasis is placed on agents that have been approved in the United States of America (USA) and the European Union, or that have reached phase III clinical studies. Several new therapies have been approved in recent years across different stages of the natural history of the disease...
May 2013: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/22654962/post-docetaxel-therapy-in-castration-resistant-prostate-cancer-the-forest-is-growing-in-the-desert
#9
Amelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, Enrico Cortesi
In Europe, prostate cancer is the most common cancer among men with 382.000 new cases and 89.000 deaths annually. Historically, androgen deprivation therapy and docetaxel based chemotherapy were the only treatments able to improve survival. Two studies have been published during last few months regarding the management of castration resistant prostate cancer (CRPC) progressed after docetaxel: for the first time second line therapies have been demonstrated to improve prognosis of these patients. The relevance of these trials is the reintroduction of chemotherapy and hormonal therapy in a disease once considered chemotherapy and castration resistant...
June 2012: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/22522582/-strategy-in-advanced-castration-resistant-prostate-cancer
#10
REVIEW
Marine Gross-Goupil, Sophie Roca, Gilles Pasticier, Alain Ravaud
If androgen deprivation, chemical with LH-RH analogs or surgical with bilateral orchiectomy, still remains the stone edge of treatment of prostate cancer, in the metastatic setting, this hormonosensitivity, most of the time long, finally move on in hormonal-failure. If rare changes in the therapeutic strategy have been achieved in this setting since 2004 and the arrival of docetaxel, it is the global perception of the disease that has been modified and the definition of one specific entity: the castrate-resistant prostate cancer...
July 2012: Bulletin du Cancer
https://www.readbyqxmd.com/read/22516516/-prostate-cancer-and-chemotherapy-standards-care-and-perspectives
#11
REVIEW
Yacine Hadjarab, Stéphane Oudard
Docetaxel is a reference treatment of metastatic prostate cancer castration-resistant. Until now, the different associations were studied without benefit when compared to docetaxel as monotherapy. Cabazitaxel showed efficacy in second-line in patients with progressive disease during or after docetaxel chemotherapy. Other molecules are being evaluated in second-line post-docetaxel. Abiraterone acetate is an alternative treatment to cabazitaxel in metastatic second-line resistant to castration. Predictive factors to choice treatment must be evaluated and proposed to personalize treatment in the future...
July 2012: Bulletin du Cancer
https://www.readbyqxmd.com/read/22048000/novel-therapeutic-strategies-for-metastatic-prostate-cancer-in-the-post-docetaxel-setting
#12
REVIEW
Oliver Sartor, Ross M Michels, Christophe Massard, Johann Sebastian de Bono
Prostate cancer is the most common noncutaneous cancer and the second leading cause of death from cancer in men in most western countries. Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state. Most current prostate cancer treatments are based on cytotoxicity directed against tumor cells via androgen-deprivation therapy or chemotherapy. Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC)...
2011: Oncologist
https://www.readbyqxmd.com/read/21426298/role-of-second-line-systemic-treatment-post-docetaxel-in-metastatic-castrate-resistant-prostate-cancer-current-strategies-and-future-directions
#13
REVIEW
Jawaher Ansari, Syed A Hussain, Abdulla Alhasso, Rana Mahmood, Asif Ansari, John Glaholm
Treatment of metastatic castrate resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy is a challenging clinical scenario with limited availability of treatment options. Re-treatment with docetaxel, either as monotherapy or in combination with other cytotoxics or targeted agents has shown durable responses. However, most docetaxel re-treatment studies have been either retrospective or early phase non-randomised studies which have not formally assessed Quality of life or survival gain with re-treatment...
March 2011: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/20404974/a-review-of-the-patterns-of-docetaxel-use-for-hormone-resistant-prostate-cancer-at-the-princess-margaret-hospital
#14
S N Chin, L Wang, M Moore, S S Sridhar
BACKGROUND: Based on the TAX 327 phase III trial, docetaxel-based chemotherapy is the standard first-line treatment for hormone-resistant prostate cancer (HRPC); however, there is some heterogeneity in the use of this agent in routine clinical practice. The aim of the present study was to examine the patterns of docetaxel use in routine clinical practice at our institution and to compare them with docetaxel use in the TAX 327 clinical trial. METHODS: We conducted a retrospective chart review of HRPC patients treated with first-line docetaxel between 2005 and 2007 at the Princess Margaret Hospital...
April 2010: Current Oncology
https://www.readbyqxmd.com/read/19605506/a-phase-ii-study-of-pemetrexed-as-second-line-chemotherapy-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-crpc-hoosier-oncology-group-gu03-67
#15
N M Hahn, R T Zon, M Yu, F O Ademuyiwa, T Jones, W Dugan, C Whalen, R Shanmugam, T Skaar, C J Sweeney
BACKGROUND: No standard therapy exists for post-docetaxel castrate-resistant prostate cancer (CRPC) patients. This trial aimed to determine the safety and efficacy of pemetrexed in post-docetaxel CRPC patients. MATERIALS AND METHODS: CRPC patients with progression after docetaxel (Taxotere) therapy received pemetrexed (500 mg/m2) i.v. every 3 weeks. The primary end point was prostate-specific antigen (PSA) response. A pharmacogenetic analysis of the reduced folate carrier-1 gene (RFC1) G80A polymorphism was also carried out...
December 2009: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/17440058/an-imaging-biomarker-of-early-treatment-response-in-prostate-cancer-that-has-metastasized-to-the-bone
#16
Kuei C Lee, Sudha Sud, Charles R Meyer, Bradford A Moffat, Thomas L Chenevert, Alnawaz Rehemtulla, Kenneth J Pienta, Brian D Ross
Prostate cancer ranks as the most common lethal malignancy diagnosed and the second leading cause of cancer mortality in American men. Although high response rates are achieved using androgen blockade as first-line therapy, most men progress toward hormone-refractory prostate cancer. Systemic chemotherapies have been shown to improve clinical outcome in hormone refractory prostate cancer patients; however, they are not curative. Due to the high incidence of bone involvement in hormone-refractory prostate cancer, assessment of treatment response in metastatic prostate cancer to the bone remains a major clinical need...
April 15, 2007: Cancer Research
https://www.readbyqxmd.com/read/12787712/current-strategies-in-the-management-of-hormone-refractory-prostate-cancer
#17
REVIEW
Cynthia L Martel, Paul H Gumerlock, Frederick J Meyers, Primo N Lara
Prostate cancer is the most common cancer diagnosed in American males, and is the second leading cause of cancer-related deaths. Most patients who develop metastatic disease will initially respond to androgen deprivation, but response is invariably temporary. Most patients will develop androgen-independent ("hormone-refractory") disease that results in progressive clinical deterioration and ultimately death. This progression to androgen independence is accompanied by increasingly evident DNA instability and alterations in genes and gene expression, including mutations in p53, over-expression of Bcl2, and mutations in the androgen receptor gene, among others...
June 2003: Cancer Treatment Reviews
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"